Business
NFL Biosciences : announces results from a new study conducted with the CEA providing further insight into the effects of NFL-101, its first-in-class treatment for tobacco addiction, and highlighting its prolonged activity
NFL Biosciences : announces results from a new study conducted with the CEA providing further insight into the effects of NFL-101, its first-in-class
About this update from Nfl Biosciences Sa
[{"type":"text","content":"\n Press release\n \n \n \n NFL Biosciences announces results from a new study conducted with the CEA providing further insight into the effects of NFL-101, its first-in-class treatment for tobacco addiction, and highlighting its prolonged activity\n \n \n A more comprehensive study conducted with the CEA enabled a more detailed characterization of NFL-101's effects\n \n \n The study model confirmed the prolonged activity of NFL-101\n \n \n The unique and original nature of NFL-101's effect is clearly demonstrated\n \n \n \n Montpellier, France, May 5, 2025, à 8:30 am CEST - NFL BIOSCIENCES (Euronext Growth Paris -FR0014003XT0 - ALFNL), a biopharmaceutical company developing innovative botanical medicines for the treatment of addiction, today announced the results of a new study conducted with the CEA, providing a deeper understanding of the effects of NFL-101, its drug candidate for tobacco addiction.\n \"These results enable a more precise identification of the brain regions targeted by NFL-101. They reveal a global and long-lasting effect on the neurobiological mechanisms involved in tobacco withdrawal, setting NFL-101 apart from conventional treatments that act solely on nicotinic receptors and require repeated administration to maintain efficacy. These are particularly compelling additional elements in the context of our ongoing discussions with pharmaceutical companies regarding a strategic partnership.\" commented Bruno Lafont, Chief Executive Officer of NFL Biosciences.\n NFL-101 is an innovative drug candidate for smoking cessation, administered in just two doses. Its efficacy was demonstrated versus placebo in the Phase 2 CESTO2 study, with continuous abstinence rates of 24.1% for dose 1 versus 12.9% for placebo (p = 0.038 < 0.05) over the primary endpoint period, from day 15 to day 43, confirmed through urinary cotinine measurement. NFL-101's mechanism of action is based on a novel immune-based approach. Its activity was first tested in a mouse model developed by the CEA (press release dated January 30, 2024), in a molecular imaging study that highlighted the restoration of normal thalamic activity in the brain region associated with the urge to smoke under withdrawal conditions.\n \n \n In order to confirm the results obtained, to further refine the identification of the targeted brain regions, and to assess any p...